黑龙江珍宝岛药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603567 证券简称：珍宝岛 公告编号：临 2023-074 重要内容提示： 投资者可于 2023 年 8 月 31 日中午 12:00 前，将关注的问题以电子邮件 的形式发送至黑龙江珍宝岛药业股份有限公司（以下简称"公司"）董事会办公 室邮箱（zbddsh@zbdzy.com），公司将结合实际情况，在信息披露允许的范围内， 就投资者普遍关注的问题在说明会上进行回复。 公司于 2023 年 8 月 24 日在上海证券交易所网站（www.sse.com.cn）披露了 《黑龙江珍宝岛药业股份有限公司 2023 年半年度报告》全文及摘要，为便于广 大投资者更全面深入地了解公司财务状况与经营情况，公司将于 2023 年 9 月 1 日（星期五）下午 15:00-16:00 召开 2023 年半年度业绩说明会。现将有关事项 公告如下： 一、业绩说明会类型 本次业绩说明会将采用网络互动方式召开，公司将针对 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2023-070 黑龙江珍宝岛药业股份有限公司 关于获得专利授权证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到欧洲专利 局颁发的《专利授权证书》，现就相关情况公告如下： | 发明名称 | 国际申请号 | 专利申请日 | 专利权人 | 授权公告日 | 专利号 | 专利权期限 | | --- | --- | --- | --- | --- | --- | --- | | 一种穿心莲内 | | | | | | | | 酯改构化合物 | PCT/CN2018/ | 2018 年 5 月 | 黑龙江珍宝岛药业 | 2023 年 7 月 | EP3632909 | 自申请之日 | | 的盐型、晶型 | 088168 | 24 日 | 股份有限公司 | 12 日 | | 起二十年 | | 及其制备方法 | | | | | | | 1 危害重、病死率较高的肺部疾病之一。 截至目前，公司穿心莲内酯改构化合物项目已完成全 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2023-069 黑龙江珍宝岛药业股份有限公司 关于持股 5%以上股东集中竞价减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 持股 5%以上股东的持股情况 本次减持计划实施前，虎林龙鹏投资中心（有限合伙）（以下简称"虎林龙 鹏"）持有黑龙江珍宝岛药业股份有限公司（以下简称"公司"）股份 96,901,820 股，占公司总股本的 10.29%。 集中竞价减持计划的实施结果情况 2023 年 4 月 15 日，公司披露了《关于持股 5%以上股东集中竞价减持股份计 划公告》（公告编号：临 2023-020 号），公司持股 5%以上股东虎林龙鹏将根据市 场价格情况，自减持计划公告之日起 15 个交易日之后的 3 个月内通过集中竞价 交易方式减持不超过公司总股本 1%的股份。 2023 年 6 月 28 日和 2023 年 7 月 7 日，公司分别披露了《关于持股 5%以上 股东集中竞价减持股份进展公告》（公告编号：临 2023-057 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2023-035 黑龙江珍宝岛药业股份有限公司 特此公告。 黑龙江珍宝岛药业股份有限公司董事会 2023 年 5 月 9 日 为进一步加强与投资者的互动交流，黑龙江珍宝岛药业股份有限公司（以 下简称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与深圳市全景 网络有限公司联合举办的"2023 年黑龙江辖区上市公司投资者集体接待日活动 暨业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP,参与本次互动交流。活动时间为 2023 年 5 月 15 日（周一）14:00-16:30。 届时公司总经理闫久江先生、财务总监王磊先生及董事会秘书张钟方女士将 在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况、融资计划、股权 激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投 资者踊跃参与！ 关于参加黑龙江辖区上市公司 2023 年投资者网上 集体接待日活动暨业绩说明会的公告 本公司 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2023-035 黑龙江珍宝岛药业股份有限公司 关于参加黑龙江辖区上市公司 2023 年投资者网上 集体接待日活动暨业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，黑龙江珍宝岛药业股份有限公司（以 下简称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与深圳市全景 网络有限公司联合举办的"2023 年黑龙江辖区上市公司投资者集体接待日活动 暨业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP,参与本次互动交流。活动时间为 2023 年 5 月 15 日（周一）14:00-16:30。 届时公司总经理闫久江先生、财务总监王磊先生及董事会秘书张钟方女士将 在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况、融资计划、股权 激励和可持续发展等投资者关心的问题，与投 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥1,532,479,010.19, representing a year-on-year increase of 52.69%[4] - The net profit attributable to shareholders for Q1 2023 was ¥254,149,498.07, reflecting a growth of 60.87% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥238,212,167.05, which is an increase of 80.97% year-on-year[4] - The basic earnings per share for Q1 2023 was ¥0.2698, up by 60.88% from the previous year[4] - The weighted average return on equity increased by 1.30 percentage points to 3.52%[4] - The net profit attributable to shareholders increased by 60.87% year-over-year, driven by market environment changes and expanded sales scale[28] - The company reported a 52.69% increase in operating revenue compared to the previous year[28] - Total revenue for Q1 2023 reached ¥1,533,841,569.17, a significant increase from ¥1,004,694,007.42 in Q1 2022, representing a growth of approximately 52.6%[37] - The net profit for the current period is 254,567,799.24, compared to 157,909,349.25 in the previous period, representing an increase of approximately 61.2%[38] - The total profit amount is 299,979,137.44, up from 188,867,728.87, indicating a growth of about 58.8%[38] - The operating profit for the current period is 299,752,876.23, compared to 188,880,551.48 in the previous period, reflecting an increase of approximately 58.5%[38] - The basic earnings per share is 0.27, compared to 0.17 in the previous period, showing a growth of 58.8%[47] - The company has a total comprehensive income of 254,567,799.24, compared to 157,909,349.25 in the previous period, reflecting an increase of approximately 61.2%[38] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥153,277,856.55, a decline of 298.49% compared to the same period last year[4] - The company's cash and cash equivalents as of March 31, 2023, were ¥839,392,400.29, down from ¥1,001,392,531.66 at the end of 2022[13] - The cash and cash equivalents at the end of the period decreased to 824,842,855.30 RMB from 1,500,174,546.91 RMB at the end of the previous year[20] - Total assets increased by 3.42% year-over-year, reaching 12,075,103,088.03 RMB[26] - The company's total assets increased to ¥12,075,103,088.03 from ¥11,675,475,538.98, marking a rise of about 3.4%[35] - The total liabilities increased to ¥4,714,056,865.82 from ¥4,568,623,170.29, reflecting a rise of approximately 3.2%[36] - Current liabilities decreased to ¥3,454,888,708.77 from ¥3,866,737,710.44, showing a reduction of approximately 10.7%[36] - Long-term borrowings rose significantly to ¥1,020,000,000.00 from ¥460,000,000.00, indicating an increase of approximately 121.7%[36] - The total equity attributable to shareholders increased by 3.58% year-over-year, amounting to 7,352,710,673.96 RMB[26] - The total equity attributable to shareholders increased to ¥7,352,710,673.96 from ¥7,098,917,047.88, representing a growth of about 3.6%[36] Expenses and Investments - Total operating costs for Q1 2023 were ¥1,225,023,970.30, up from ¥851,272,779.55 in Q1 2022, indicating an increase of about 44%[37] - Research and development expenses for Q1 2023 amounted to ¥14,040,635.04, compared to ¥11,020,378.79 in Q1 2022, reflecting a growth of approximately 27.3%[37] - Cash flow from investment activities showed a net inflow of 18,843,359.75 RMB, recovering from a net outflow of -75,155,946.82 RMB in the previous year[20] Shareholder Activities - The company repurchased 2,559,700 shares, accounting for 0.27% of the total share capital, with a total expenditure of 29,991,325.30 RMB[33] - The company raised 1,205,000,000.00 RMB through financing activities, significantly up from 430,000,000.00 RMB in the same period last year[20] Impairment and Losses - The company reported a credit impairment loss of -30,166,769.26, compared to -5,570,740.66 in the previous period, which is a significant increase in losses[38] - The company recorded an asset impairment loss of 528,581.20, a decrease from -10,114,879.31 in the previous period, indicating improved asset performance[38] Other Information - The company reported non-recurring gains of ¥15,937,331.02 after tax for the reporting period[7] - The company reported a net profit margin improvement, with net income for Q1 2023 showing a positive trend compared to the previous year, although specific figures were not disclosed[37] - The company is focusing on market expansion and new product development, as indicated by the increase in sales and R&D expenses[37] - The company has not applied new accounting standards or interpretations for the current period[50]

R&D and Innovation - The company plans to complete the reserve of 40-50 drug varieties annually and initiate at least 6 self-developed generic drug projects[2] - The company has established a tiered R&D product sequence to ensure continuous market competitiveness by systematically applying for new drug varieties[2] - The company's R&D system continued to introduce high-level talents in 2022, optimizing the self-developed expert team and advancing the development of generic and innovative drug projects through international collaborations[109] - Completed registration and submission for 11 generic drug projects, with 11 receiving acceptance notices, including the FDA submission for Tofacitinib Citrate Tablets, a dual China-US project[191] - Initiated Phase I clinical trials for the anti-tumor innovative drug ZBD1006, with 5 dose escalation groups completed[191] - Increased R&D expenses by 28.46% to 709.48 million yuan compared to the previous year[200] - The company is actively expanding international cooperation to introduce innovative and generic drug projects that align with its strategic direction[193] - The company is exploring collaborations with multinational pharmaceutical companies, biotech firms, and academic institutions to develop innovative drugs[193] Quality Control and Safety - The company has implemented a dual-constraint system of "physical and chemical indicators + brand indicators" to ensure the quality and stability of raw materials[4] - The company has developed an online monitoring system for the extraction process and a network chromatography instrument detection system to enhance quality control[4] - The company has established a drug safety monitoring and re-evaluation system to ensure the safety of drugs throughout their lifecycle[4] Financial Performance and Dividends - The total remuneration for directors, supervisors, and senior management in the reporting period was 5.7856 million yuan[21] - The company's cash dividend for 2022 is RMB 26,303,308.98, with a dividend payout ratio of 14.19% of the net profit attributable to ordinary shareholders[29] - The total dividend amount, including cash dividends and share repurchases, is RMB 56,294,634.28, accounting for 30.37% of the net profit attributable to ordinary shareholders[29] - The company plans to distribute a cash dividend of 0.28 yuan per 10 shares, totaling 26,303,308.98 yuan[137] - Total cash dividends, including share repurchases, amount to 56,294,634.28 yuan, representing 30.37% of net profit attributable to shareholders[137] Environmental Protection and Compliance - The company's environmental protection investment in 2022 amounted to RMB 1,456.26 million[50] - The company's wastewater and exhaust emissions comply with national standards, with regular third-party testing conducted[36][52][58][59] - The company has established a comprehensive environmental protection management system, including waste management and emergency response plans[55][56] - The company's internal control system is effective, with an unqualified opinion from the audit firm[32][49] Market Performance and Sales - The company's blood stasis injection product saw a price adjustment from "limited to secondary and above medical institutions for stroke paralysis or central retinal vein occlusion patients" to "limited to secondary and above medical institutions"[70] - The company's bone and muscle system disease treatment segment generated revenue of 602.244 million yuan, with a gross profit margin of 75.34%, but revenue decreased by 27.56% year-over-year[71] - The company's traditional Chinese medicine products ranked first in hospital market share, with a year-over-year sales growth of 3.3% in the fourth quarter of 2022[85] - The company's anti-tumor and immunomodulator products ranked second in hospital market share, with a year-over-year sales decline of 1.9% in the fourth quarter of 2022[85] - The company's systemic anti-infective drugs ranked third in hospital market share, with a year-over-year sales decline of 2.1% in the fourth quarter of 2022[85] - The company's digestive and metabolic drugs ranked fourth in hospital market share, with a year-over-year sales decline of 5.6% in the fourth quarter of 2022[85] - The company's blood stasis injection product (200mg) had a procurement volume of 1.769 million units, with a price range of 20.08 to 28 yuan per unit[71] - The company's blood stasis injection product (100mg) had a procurement volume of 2.089 million units, with a price range of 27.96 to 48.2 yuan per unit[71] - The company's blood stasis capsule product had a procurement volume of 12.938 million units, with a price range of 1.5922 to 1.6642 yuan per unit[71] - Sales of "Zhusheyong Xuesaitong" (injection) increased by 20.70% year-on-year, reaching 2,884.38 million units[173] Corporate Governance and Shareholder Rights - The company has implemented a comprehensive governance structure, ensuring equal rights for all shareholders and transparent decision-making processes[9] - The company has maintained strict compliance with insider information management and disclosure regulations[11] - The company held 8 board meetings in 2022, with 5 conducted via telecommunication and 3 combining on-site and telecommunication methods[41] - The company's dividend policy is in compliance with the company's articles of association and shareholder meeting resolutions, with clear standards and proportions[161] Financial Metrics and Cash Flow - The company's basic earnings per share (EPS) decreased by 48.74% year-over-year to 0.1969 yuan in 2022[99] - The company's diluted EPS also decreased by 48.74% year-over-year to 0.1969 yuan in 2022[99] - The weighted average return on equity (ROE) decreased by 3.04 percentage points to 2.62% in 2022[99] - The company's industrial revenue reached 234,111.89 million yuan, with a pharmaceutical industrial gross margin of 65.34%[108] - The overall gross margin of the company was 59.44% in 2022[108] - The company's sales of cardiovascular and cerebrovascular drugs increased by 74.13% year-over-year to 72,869.97 million yuan[108] - Q1 2022 revenue was RMB 1,003,658,954.36, Q2 revenue was RMB 1,474,995,212.74, Q3 revenue was RMB 837,929,544.71, and Q4 revenue was RMB 897,565,147.91[115] - Net profit attributable to shareholders in Q1 2022 was RMB 157,983,557.32, Q2 was RMB 81,173,585.54, Q3 was a loss of RMB -85,661,561.06, and Q4 was RMB 31,895,075.33[115] - Net cash flow from operating activities in Q1 2022 was RMB 77,223,705.06, Q2 was a negative RMB -98,605,456.45, Q3 was a negative RMB -5,181,535.20, and Q4 was a negative RMB -300,229,473.94[115] - Revenue for 2022 reached 4,214,148,859.72 yuan, a 2.12% increase compared to 2021[133] - Net cash flow from operating activities was -326,792,760.53 yuan, a 24.69% improvement from the previous year[140] - Net cash flow from investing activities was 283,931,024.95 yuan, a significant 167.40% increase compared to 2021[140] - Net cash flow from financing activities was -418,944,606.70 yuan, a 152.54% decrease from the previous year[140] Inventory and Asset Management - Inventory increased by 37.16% to RMB 1,005,750,391.69 in 2022, mainly due to strategic reserve increases[120] - Intangible assets grew by 265.06% to RMB 764,289,818.20, driven by increased product patent technology[120] - Development expenditure increased by 42.45% to RMB 198,491,520.56, reflecting higher R&D investment[120] - Short-term borrowings surged by 116.67% to RMB 1,301,648,472.23, primarily due to increased short-term credit loans[120] - Contract liabilities rose by 343.27% to RMB 54,886,001.28, mainly due to increased advance payments from customers[120] - Long-term borrowings decreased by 64.35% to RMB 460,000,000.00, as the company repaid long-term loans and reclassified some to short-term liabilities[120] - Monetary funds decreased by 35.44% to 1,001,392,531.66 yuan, mainly due to increased investment in fundraising projects[141] - Accounts receivable increased by 59.58% to 135,397,401.38 yuan, primarily due to increased bill settlements[141] - Restricted monetary funds totaled 19,078,340.09 yuan, mainly due to housing deposits and bank acceptance bill guarantees[143] Talent and Compensation - The company has strengthened its talent strategy by combining internal training with external recruitment, focusing on R&D and marketing talent[7] - The company's board of directors includes Chairman Fang Tonghua, who has been in the position since March 2011, with an annual pre-tax compensation of 2.7074 million yuan[152] - The company's total pre-tax compensation for all directors, supervisors, and senior management in 2022 was 8.2162 million yuan[152] - The company is focusing on improving its salary policies to maintain regional industry leadership and integrating incentive mechanisms with the salary system[156] Accounts Receivable and Bad Debt - Accounts receivable within 1 year amounted to 1,398,279,028.46 yuan, with a bad debt provision ratio of 0.50%[166] - Accounts receivable aged 1 to 2 years totaled 188,415,496.95 yuan, with a bad debt provision ratio of 5.00%[166] - Accounts receivable aged 2 to 3 years were 16,767,435.19 yuan, with a bad debt provision ratio of 20.00%[166] - Total accounts receivable stood at 1,606,977,800.91 yuan, with a total bad debt provision of 23,281,498.74 yuan[166] Industry Trends and Market Analysis - MAT sales of multinational companies in China decreased by 4.3% year-over-year in 2022, while domestic companies saw a smaller decline of 1.3%[89] - The Chinese pharmaceutical market is expected to grow at a rate of 7-8% in terms of actual drug sales volume, driven by innovation drugs and influenced by healthcare cost control and volume-based procurement[90] - In 2022, the National Medical Products Administration approved 51 new drugs, including 7 traditional Chinese medicine (TCM) new drugs[90] - Innovation drugs accounted for 25% of the total hospital drug sales in China in 2021, up 5 percentage points from 2017, with domestic innovation drugs increasing their share from 17% to 23%[90] Product and Market Share - The company has 65 products in the 2022 national medical insurance catalog, including 34 Class A and 31 Class B products, with 2 products having adjusted medical insurance notes compared to 2021[68] - The top five customers accounted for 16.44% of total annual sales, with no related party sales[176] - The top five suppliers accounted for 8.37% of total annual purchases, with no related party purchases[177] - The company has 160 R&D personnel, accounting for 5.8% of the total workforce[179] Expenses and Costs - Sales expenses decreased by 5.62% to 608.31 million yuan year-on-year[200] - Management expenses slightly decreased by 0.86% to 321.99 million yuan[200] - Financial expenses decreased by 5.04% to 135.32 million yuan[200] - Revenue from Chinese herbal medicine trade increased by 28.16%, while costs rose by 32.53% due to seasonal and regional price fluctuations[172] Government Subsidies and Other Receivables - The company has a policy for handling government subsidies, where any confirmed subsidies that need to be returned will offset the relevant deferred income balance, with any excess recorded in current profits and losses[163] - Total other receivables amounted to 823.41 million yuan, with government subsidies accounting for 658.84 million yuan[198] Leasing and Asset Recognition - The company recognizes the right to use leased assets as a lessee at the commencement of the lease term, except for simplified short-term leases and low-value asset leases[165] Business Overview and Product Information - The company's main business is in the pharmaceutical manufacturing industry, specifically in the production of traditional Chinese medicine[144] - The product "Injection of Xuesaitong (Freeze-dried)" is used for promoting blood circulation and removing blood stasis, and is classified as a prescription drug and protected traditional Chinese medicine[145] - The company's registered address is in Heilongjiang Province, and its office address is in Harbin, Heilongjiang Province[150]

2022 年第三季度报告 证券代码：603567 证券简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是√否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | --- | |-----------------------------|-----------------|---------------------------------------|-------|------------------|--------------------------------------------| | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 2,478,654,167.10, representing a 52.06% increase compared to CNY 1,630,014,986.26 in the same period last year[19]. - The net profit attributable to shareholders decreased by 13.43% to CNY 239,157,142.86 from CNY 276,272,225.25 year-on-year[19]. - The net cash flow from operating activities improved significantly, with a net outflow of CNY -21,381,751.39, a 94.67% reduction compared to CNY -400,995,833.55 in the previous year[19]. - Basic earnings per share decreased by 21.95% to CNY 0.2539 from CNY 0.3253 in the same period last year[20]. - The weighted average return on net assets fell to 3.34% from 4.90% year-on-year, indicating a decline in profitability[20]. - The company reported a 27.62% increase in net profit after deducting non-recurring gains and losses, reaching CNY 217,546,853.48 compared to CNY 170,459,049.71 in the previous year[19]. - The company reported a non-recurring profit of CNY 21,610,289.38 after accounting for tax effects and minority interests[23]. - The company’s cash and cash equivalents increased slightly to ¥1,553,131,679.12, accounting for 13.13% of total assets, compared to 13.48% in the previous year[79]. - The company’s accounts receivable rose to ¥3,801,089,443.43, representing 32.12% of total assets, up from 29.27% the previous year[79]. - The company’s investment activities generated a net cash flow of ¥215,580,284.33, a significant increase of 255.24% from -¥138,871,309.38 in the previous year[76][77]. Asset Management - The company's total assets increased by 2.84% to CNY 11,832,676,803.40 from CNY 11,506,076,750.01 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 1.98% to CNY 7,182,460,122.18 from CNY 7,042,918,942.75 at the end of the previous year[19]. - The total assets of Harbin Zhenbao Pharmaceutical Co., Ltd. decreased by 4.16% to CNY 1,720,758.1, with a net profit of CNY -41,097,900, a decrease of 381.95% year-on-year[87]. - The total assets of Bozhou Traditional Chinese Medicine Commodity Trading Center Co., Ltd. decreased by 8.44% to CNY 2,137,417.6, while its revenue increased by 70.25% to CNY 772,195,000[88]. - The total current assets amounted to RMB 6,801,540,768.26, compared to RMB 6,676,074,667.39 at the beginning of the period, representing an increase of approximately 1.9%[156]. Research and Development - The company has established a national-level postdoctoral research station and provincial-level technology centers to strengthen its R&D capabilities[54]. - The R&D team consists of nearly 200 members, with over 100 holding doctoral or master's degrees, emphasizing the importance of talent cultivation[54]. - The company is currently developing 3 innovative drug varieties in gynecology, oncology, and digestive metabolism, filling market gaps in traditional Chinese medicine treatment[55]. - The company is actively pursuing innovation in traditional Chinese medicine, with a significant increase in registration applications for innovative traditional Chinese medicines[45]. - The company has developed 49 hospital preparation varieties and is conducting research on 3 registration projects, aiming to modernize and industrialize traditional Chinese medicine[55]. Market Strategy - The increase in operating revenue was primarily due to the expansion of the traditional Chinese medicine business[21]. - The company is focusing on high-demand areas such as cardiovascular and respiratory medications, driven by an aging population and increasing disease prevalence[47]. - The company is expanding its sales channels through the establishment of a comprehensive business system and distribution network, enhancing service quality[34]. - The company has established a comprehensive marketing management service system to enhance service quality and ensure accessibility[62]. - The company has been recognized as one of the top 100 most influential pharmaceutical enterprises in China and ranked 26th in the "Top 100 Chinese Traditional Medicine Enterprises" list[46]. Environmental Responsibility - The company has established a dedicated environmental management organization and appointed a full-time environmental protection officer to enhance its environmental responsibility[112]. - The company’s wastewater discharge complies with the standards set by GB-21906—2008, and it conducts annual third-party testing of its wastewater discharge indicators[114]. - The company’s air emissions from its biomass boilers meet the GB37823-2019 standards, with annual third-party testing conducted for compliance[115]. - The company has achieved a zero discharge of hazardous waste by maintaining strict records of generation and storage processes[127]. - The company’s solid waste is managed by municipal sanitation departments, while hazardous waste is transferred to qualified disposal companies[121]. Corporate Governance - The company has not faced any penalties or corrective actions related to legal violations during the reporting period[135]. - The company has not disclosed any new products or technologies in the current report[135]. - The company did not propose any profit distribution or capital reserve transfer plans for the first half of 2022, with no dividends or stock bonuses planned[108]. - The company has engaged in poverty alleviation efforts, providing support to four households in need with慰问品 valued at 2,194 yuan in the first half of 2022[130]. - The company has committed to not engaging in competitive activities with its subsidiaries, ensuring a focus on mutual benefits[132]. Shareholder Information - The total number of shares after the recent changes is 941,963,592, with 100% being tradable shares[143]. - The largest shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 61.56% of the shares, totaling 579,885,300 shares[148]. - The company has a total of 92,803,592 restricted shares that were released for trading on May 11, 2022[145]. - The company completed a non-public offering of 92,803,592 shares, increasing the total share capital from 849,160,000 to 941,963,592 shares[144]. - The company has not reported any changes in earnings per share or net asset per share due to share changes during the reporting period[144].

Financial Performance - The company's operating revenue for 2021 was RMB 4,126,813,896.18, representing a 21.24% increase compared to RMB 3,403,747,280.97 in 2020[21]. - The net profit attributable to shareholders of the listed company decreased by 23.88% to RMB 332,099,672.96 from RMB 436,285,785.59 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was RMB 79,236,536.87, a significant decrease of 77.92% compared to RMB 358,933,556.59 in 2020[21]. - The net cash flow from operating activities was negative at RMB -433,936,940.94, a decline of 379.64% from RMB 155,178,025.16 in the previous year[21]. - Basic earnings per share decreased by 25.24% to 0.3841 RMB compared to 2020[24]. - The weighted average return on equity dropped to 5.664% from 8.15% in 2020, a decrease of 2.49 percentage points[24]. - The total assets at the end of 2021 were RMB 11,506,076,750.01, an increase of 12.43% from RMB 10,234,312,842.17 at the end of 2020[21]. - The net assets attributable to shareholders of the listed company increased by 28.18% to RMB 7,042,918,942.75 from RMB 5,494,448,424.79 in 2020[21]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 1.06 per 10 shares, totaling RMB 99,848,140.76[6]. - The company has not proposed any stock bonus or capital reserve transfer to increase share capital for the 2021 fiscal year[6]. Market Position and Strategy - The company has been recognized as the 26th in the "Top 100 Chinese Traditional Medicine Enterprises" list, highlighting its market position[46]. - The company is focusing on optimizing production capacity and product structure to adapt to the new drug procurement environment[40]. - The company plans to implement a market development strategy that includes "self-operated + all-channel + all-terminal" approaches[40]. - The company is actively responding to the new centralized procurement policies for traditional Chinese medicine, developing differentiated competitive strategies[47]. Research and Development - The company has established a comprehensive R&D system with over 200 professionals, focusing on seven major R&D platforms[53]. - The company has shifted its R&D focus from generic drugs to innovative drugs, particularly in the antiviral and anti-tumor fields[136]. - The company has several ongoing clinical trials, including innovative drugs ZBD1042 and HZB1006, both currently in Phase I[162]. - The company has introduced a significant number of high-level talents in the R&D field, enhancing its overall R&D capabilities[161]. Sales and Marketing - The company has optimized its marketing strategies, enhancing its sales management system to cover all levels of medical institutions and retail markets across 32 provinces[79]. - The company is focusing on expanding its retail market presence through a comprehensive sales network[172]. - The company is implementing a refined marketing strategy combining precise招商管理 and自主营销, focusing on both high-level hospitals and grassroots medical markets to expand its retail channels, particularly targeting chain pharmacies[195]. Operational Efficiency - The company has implemented advanced management practices, including a digitalized supply chain system, to improve efficiency and reduce errors in production[84]. - The company is enhancing its sales capabilities by optimizing product lines and expanding retail terminal sales networks[64]. - The company is leveraging data analysis to predict market trends and optimize inventory management for its traditional Chinese medicine trading business[65]. Financial Management and Investments - The company has initiated a strategic partnership with Deloitte to enhance its financial management capabilities through the implementation of an integrated financial system[43]. - The company successfully raised 1.238 billion CNY through a non-public stock issuance, enhancing its strategic operational layout and expanding production capacity[58]. - The company has increased its investment in equity instruments by 44.20%, reaching 591,200,000.00 CNY[141]. Challenges and Risks - The company faces significant risks from frequent pharmaceutical policy changes, including the requirement for public medical institutions to procure 90% of drugs through provincial centralized procurement platforms, impacting the profitability of generic drugs[198]. - The introduction of supportive policies for traditional Chinese medicine aims to promote sustainable development in the industry, marking a new historical development period[199].